V. Boussiotis
Immunology · 2001–2022
A researcher in the Science corpus: 6 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 97 citations into it
- Oncology — 46 citations into it
Whom V. Boussiotis trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from V. Boussiotis's perspective
Ordered by how strongly the researchers V. Boussiotis trusts endorse each paper. Same corpus, a different order for every researcher.
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
- Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets (Journal of Immunology)
- The mechanisms of action of PPARs. (Annual Review of Medicine)
- Nuclear receptors and lipid physiology: opening the X-files. (Science)
- Macrophage Polarization. (Annual Review of Physiology)
- Integrins: dynamic scaffolds for adhesion and signaling in platelets. (Blood)
- Faculty Opinions recommendation of Talin binding to integrin beta tails: a final common step in integrin activation.
- Calpain-mediated proteolysis of talin regulates adhesion dynamics (Nature Cell Biology)
- C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. (Genes & Development)
Their papers
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation (2015) — 1,091 citations
- The complex role of tumor-infiltrating macrophages (2022) — 740 citations
- The role of Peroxisome Proliferator-Activated Receptors (PPAR) in immune responses (2020) — 601 citations
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway (2016) — 1,138 citations
- Reconstructing and Deconstructing Agonist-Induced Activation of Integrin αIIbβ3 (2006) — 488 citations
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation (2001) — 2,945 citations